Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond

Bibliography

• Jemal A, Thun MJ, Ries LA, Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100(23):1672-94
   PubMed Web of Science ®Google Scholar
• SEERDatabase. Available from: http://seer.cancer.gov. [Accessed 03 Febryary 2010]
   Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17(7):2105-16
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hsu J, Lee S, Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26(35):5748-54
   PubMed Web of Science ®Google Scholar
• Camacho LH, Antonia S, Sosman J, Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009;27(7):1075-81
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America 2003;100(8):4712-17
   Google Scholar
• Ribas A, Camacho LH, Lopez-Berestein G, Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23(35):8968-77
   PubMed Web of Science ®Google Scholar
• Serrone L, Zeuli M, Sega FM, Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19(1):21-34
   PubMed Web of Science ®Google Scholar
• Chapman PB, Einhorn LH, Meyers ML, Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17(9):2745-51
   PubMed Web of Science ®Google Scholar
• Chiarion Sileni V, Nortilli R, Aversa SM, Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 2001;11(2):189-96
   PubMed Web of Science ®Google Scholar
• Creagan ET, Suman VJ, Dalton RJ, Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 1999;17(6):1884-90
   PubMed Web of Science ®Google Scholar
• Falkson CI, Ibrahim J, Kirkwood JM, Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16(5):1743-51
   PubMed Web of Science ®Google Scholar
• McDermott DF, Sosman JA, Gonzalez R, Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008;26(13):2178-85
   PubMed Web of Science ®Google Scholar
• Middleton MR, Lorigan P, Owen J, A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000;82(6):1158-62
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N, Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18(1):158-66
   PubMed Web of Science ®Google Scholar
• Zimpfer-Rechner C, Hofmann U, Figl R, Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 2003;13(5):531-6
   PubMed Web of Science ®Google Scholar
• Walker L, Schalch H, King DM, Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res 2005;15(5):453-9
   PubMed Web of Science ®Google Scholar
• Retsas S, Newton KA, Westbury G. Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer Chemother Pharmacol 1979;2(4):257-60
   PubMed Web of Science ®Google Scholar
• Whitehead RP, Moon J, McCachren SS, A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer 2004;100(8):1699-704
   PubMed Web of Science ®Google Scholar
• Jimeno A, Hitt R, Quintela-Fandino M, Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma. Anticancer Drugs 2005;16(1):53-7
   PubMed Web of Science ®Google Scholar
• Clamon G, Sinkey C, Jochimsen P. Phase II study of dibromodulcitol and BCNU in metastatic malignant melanoma. Am J Clin Oncol 1985;8(3):244-6
   PubMed Web of Science ®Google Scholar
• Voigt H, Meigel WN, Meissner K, Experiences with high-dose cisplatin therapy in metastasized malignant melanoma. Onkologie 1982;5(3):120-9
   PubMed Web of Science ®Google Scholar
• Hersh EM, O'Day SJ, Ribas A, A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010;116(1):155-63
   PubMed Web of Science ®Google Scholar
• Luikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984;2(3):164-8
   PubMed Web of Science ®Google Scholar
• Jungnelius U, Ringborg U, Aamdal S, Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur J Cancer 1998;34(9):1368-74
   PubMed Web of Science ®Google Scholar
• Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49(17):4682-9
   PubMed Web of Science ®Google Scholar
• Ball NJ, Yohn JJ, Morelli JG, Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994;102(3):285-90
   PubMed Web of Science ®Google Scholar
• Platz A, Ringborg U, Brahme EM, Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res 1994;4(3):169-77
   PubMed Web of Science ®Google Scholar
• van't Veer LJ, Burgering BM, Versteeg R, N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Molecular Cell Biol 1989;9(7):3114-16
   Web of Science ®Google Scholar
• Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93(14):1062-74
   PubMed Web of Science ®Google Scholar
• Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005;23(27):6771-90
   PubMed Web of Science ®Google Scholar
• Pollock PM, Harper UL, Hansen KS, High frequency of BRAF mutations in nevi. Nat Genet 2003;33(1):19-20
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
   PubMed Web of Science ®Google Scholar
• Sharma A, Trivedi NR, Zimmerman MA, Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005;65(6):2412-21
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT, Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006;95(5):581-6
   PubMed Web of Science ®Google Scholar
• Amaravadi RK, Schuchter LM, McDermott DF, Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009;15(24):7711-18
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Schiller J, Schuchter LM, A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008;14(15):4836-42
   PubMed Web of Science ®Google Scholar
• Smalley KS, Xiao M, Villanueva J, CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009;28(1):85-94
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Keilholz U, Hogg D, Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J Clin Oncol 2007;25(18 Suppl 20):8510
   Web of Science ®Google Scholar
• Flaherty KT, Lee SJ, Schuchter LM, Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin/paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2010;28:15s(Suppl): Abstr 8511
   PubMed Web of Science ®Google Scholar
• Fecher LA, Amaravadi R, Schuchter LM. Effectively targeting BRAF in melanoma: a formidable challenge. Pigment Cell Melanoma Res 2008;21(4):410-11
   PubMed Web of Science ®Google Scholar
• Tsai J, Lee JT, Wang W, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008;105(8):3041-6
   PubMed Web of Science ®Google Scholar
• Chapman P, Puzanov I, Sosman J, Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Eur J Cancer Suppl 2009 September 2009; 2009. p.5
   Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352(8):786-92
   PubMed Web of Science ®Google Scholar
• Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100(3):1014-18
   PubMed Web of Science ®Google Scholar
• Roumiantsev S, Shah NP, Gorre ME, Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002;99(16):10700-5
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Merkelbach-Bruse S, Pauls K, Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006;12(6):1743-9
   PubMed Web of Science ®Google Scholar
• Montagut C, Sharma SV, Shioda T, Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008;68(12):4853-61
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Zhang C, Bollag G, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464(7287):427-30
   PubMed Web of Science ®Google Scholar
• Heidorn SJ, Milagre C, Whittaker S, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140(2):209-21
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA, BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439(7074):358-62
   PubMed Web of Science ®Google Scholar
• Haass NK, Sproesser K, Nguyen TK, The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008;14(1):230-9
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W, Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26(13):2139-46
   PubMed Web of Science ®Google Scholar
• Banerji U, Camidge DR, Verheul HM, The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010;16(5):1613-23
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Adjei AA, Varterasian M, Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23(23):5281-93
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Krishnamurthi SS, Rinehart JJ, Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers. Clin Cancer Res 2010;16(6):1924-37
   PubMed Web of Science ®Google Scholar
• Emery CM, Vijayendran KG, Zipser MC, MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106(48):20411-16
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Bezrookove V, Green G, Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457(7229):599-602
   PubMed Web of Science ®Google Scholar
• Wymann MP, Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 2005;17(2):141-9
   PubMed Web of Science ®Google Scholar
• Guldberg P, thor Straten P, Birck A, Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997;57(17):3660-3
   PubMed Web of Science ®Google Scholar
• Tsao H, Zhang X, Benoit E, Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998;16(26):3397-402
   PubMed Web of Science ®Google Scholar
• Tsao H, Zhang X, Fowlkes K, Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000;60(7):1800-4
   PubMed Web of Science ®Google Scholar
• Davies MA, Stemke-Hale K, Tellez C, A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008;99(8):1265-8
   PubMed Web of Science ®Google Scholar
• Margolin K, Longmate J, Baratta T, CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005;104(5):1045-8
   PubMed Web of Science ®Google Scholar
• Thallinger C, Poeppl W, Pratscher B, CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 2007;79(4):207-13
   PubMed Web of Science ®Google Scholar
• Thallinger C, Werzowa J, Poeppl W, Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. J Invest Dermatol 2007;127(10):2411-17
   PubMed Web of Science ®Google Scholar
• Ernst DS, Eisenhauer E, Wainman N, Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 2005;23(6):569-75
   PubMed Web of Science ®Google Scholar
• Nakahara M, Isozaki K, Hirota S, A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998;115(5):1090-5
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299(5607):708-10
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Nishida T, Hirota S, Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59(17):4297-300
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K, Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35
   PubMed Web of Science ®Google Scholar
• Willmore-Payne C, Holden JA, Tripp S, Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 2005;36(5):486-93
   PubMed Web of Science ®Google Scholar
• Shen SS, Zhang PS, Eton O, Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 2003;30(9):539-47
   PubMed Web of Science ®Google Scholar
• Ugurel S, Hildenbrand R, Zimpfer A, Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92(8):1398-405
   PubMed Web of Science ®Google Scholar
• Wyman K, Atkins MB, Prieto V, Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106(9):2005-11
   PubMed Web of Science ®Google Scholar
• Beadling C, Jacobson-Dunlop E, Hodi FS, KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14(21):6821-8
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24(26):4340-6
   PubMed Web of Science ®Google Scholar
• Ashida A, Takata M, Murata H, Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 2009;124(4):862-8
   PubMed Web of Science ®Google Scholar
• Hodi FS, Friedlander P, Corless CL, Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26(12):2046-51
   PubMed Web of Science ®Google Scholar
• Kluger AD, McCann L, Rink J, A phase II trial of dasatinib in advanced melanoma. J Clin Oncol 2009(Suppl): Abstr 9010
   PubMed Web of Science ®Google Scholar
• Chaudhury TK, Lerner MP, Nordquist RE. Angiogenesis by human melanoma and breast cancer cells. Cancer Lett 1980;11(1):43-9
   PubMed Web of Science ®Google Scholar
• Folkman J, Merler E, Abernathy C, Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133(2):275-88
   PubMed Web of Science ®Google Scholar
• Hubler WR Jr, Wolf JE Jr. Melanoma. Tumor angiogenesis and human neoplasia. Cancer 1976;38(1):187-92
   PubMed Web of Science ®Google Scholar
• Fruehauf JP, Lutzky DF, McDermott CK, Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study. J Clin Oncol 2008;26:9006
   Google Scholar
• Varker KA, Biber JE, Kefauver C, A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007;14(8):2367-76
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cao M, Viteri S, Diaz-Lagares A, Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology 2008;74(1-2):12-6
   PubMed Web of Science ®Google Scholar
• Perez DG, Suman VJ, Fitch TR, Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009;115(1):119-27
   PubMed Web of Science ®Google Scholar
• O'Day KBK, Sosman JA, Peterson AC, BEAM: a randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Eur J Cancer Suppl 2009;7(3):13
   Web of Science ®Google Scholar
• Jansen B, Schlagbauer-Wadl H, Brown BD, bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4(2):232-4
   PubMed Web of Science ®Google Scholar
• Jansen B, Wacheck V, Heere-Ress E, Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356(9243):1728-33
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H, Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24(29):4738-45
   PubMed Web of Science ®Google Scholar
• Miller LA, Goldstein NB, Johannes WU, BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol 2009;129(4):964-71
   PubMed Web of Science ®Google Scholar
• Cragg MS, Jansen ES, Cook M, Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 2008;118(11):3651-9
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Cohen MB, Atkins MB, In vitro synergy of the combination of sorafenib and ABT-737 in melanoma cell lines. AACR Annual Meeting 2009; Abstract 5501
   Google Scholar
• Hassan M, Alaoui A, Feyen O, The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways. Oncogene 2008;27(33):4557-68
   PubMed Web of Science ®Google Scholar
• Qin JZ, Ziffra J, Stennett L, Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005;65(14):6282-93
   PubMed Web of Science ®Google Scholar
• Amiri KI, Horton LW, LaFleur BJ, Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004;64(14):4912-18
   PubMed Web of Science ®Google Scholar
• Markovic SN, Geyer SM, Dawkins F, A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005;103(12):2584-9
   PubMed Web of Science ®Google Scholar
• Gradilone A, Gazzaniga P, Ribuffo D, Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol 2003;21(2):306-12
   PubMed Web of Science ®Google Scholar
• Grossman D, McNiff JM, Li F, Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999;113(6):1076-81
   PubMed Web of Science ®Google Scholar
• Piras F, Murtas D, Minerba L, Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology 2007;50(7):835-42
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Morton DL, Elashoff D, Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 2005;117(6):1032-8
   PubMed Web of Science ®Google Scholar
• Grossman D, Kim PJ, Schechner JS, Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001;98(2):635-40
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Lewis K, Samlowski W, A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2007;25(18 Suppl 20):8538
   Web of Science ®Google Scholar
• Kirshner JR, He S, Balasubramanyam V, Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 2008;7(8):2319-27
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Lawson DH, Weber RW, Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): subgroup analysis by prior chemotherapy. J Clin Oncol 2008;26(Suppl 20):9036
   Google Scholar
• Hauschild AME, Jacobson E, O'Day SJ. Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). J Clin Oncol 2009;27(18S): abstract LBA9012
   Google Scholar